Introduction
, have shown convincing therapeutic potential and are currently under clinical evaluations.
A common characteristic of many compounds active against IN is the presence of multiple aromatic rings with polyaryl hydroxylation, frequently of the catechol type (Fesen et al., 1994; LaFemina et al., 1995; Robinson et al., 1996; Pommier et al., 1997) . Indeed, based on SAR and other studies (Farnet et al., 1998; Burke et al., 1995; Zhao et al., 1997) , the catechol moiety has been postulated to be the pharmacophore of polyhydroxylated inhibitors. Their likely site of action has been located in the catalytic core domain of IN, as suggested by their activity on the enzyme of deletion mutants (aminoacids 50-212) and dependence on divalent cations (Hazuda et al., 1997) .
Caffeic acid phenethyl ester (CAPE) was one of the first reported natural product inhibitor of IN (Fesen et al., 1993 (Fesen et al., , 1994 . Several follow-up studies demonstrated the importance of the catechol moiety for activity (Burke et al., 1995; Zhao et al., 1997) . It was also shown that a majority of reported IN inhibitors contain a three-point pharmacophore feature present in CAPE structure (Nicklaus et al., 1997; Figure 1) . In an attempt to identify new IN inhibitors of natural origin, we fixed CAPE's acrylate moiety (I) (Fesen et al., 1993) in a constrained form by incorporating its vinyl bond into an indole ring, thereby obtaining the 5,6-dihydroxyindole-2-carboxylic acid (DHICA II) ( Figure 2) .
Interestingly, II has been recognized as the key monomer intermediate in the biosynthesis of melanins, the primary pigments of skin, hair and eyes in mammals (Nicolaus, 1968; Nicolaus et al., 1964; Prota, 1992; D'Ischia et al., 1996; Tsukamoto et al., 1992) . Moreover, this diffusible melanin precursor is a potent stimulator of lipopolysaccharide-induced production of nitric oxide.
Furthermore, it has been hypothesized to play a role as a chemical messenger mediating interaction between active melanocytes and macrophages in epidermal inflammatory and immune responses (D'Aquisto et al., 1995) .
A novel synthetic route to II was performed followed by the synthesis of a series of derivatives such as: i) amides characterized by non-hydroxylated (IIIa and IIIb) or catechol-containing (IIIc and IIId) aromatic groups; ii) dimeric forms of II connected by linkers of various lengths (IIIe-IIIi) ( Figure 3 ). In this study we present the inhibitory potency of the listed compounds against purified IN. Their cytotoxicity and antiviral activity were studied in cell-based assays. Recently, we showed that mercaptosalicylhydrazides designed to chelate Mg 2+ on the active site of IN also bind to C65. Therefore, some of the most potent compounds presented in this study were also evaluated in enzyme assays against the C56S mutant. We also performed docking studies to investigate the interactions between these compounds and the amino acid residues on the IN active site.
Materials and methods
Chemistry Anhydrous solvents and all reagents were purchased from Aldrich, Merck or Carlo Erba. Anhydrous diethyl ether was obtained by distillation from Na/benzophenone under nitrogen. All reactions involving air-or moisturesensitive compounds were performed under nitrogen using oven-dried glassware and syringes to transfer solutions. Melting points (mp) were determined using an Electrothermal melting point or a Köfler apparatus and are uncorrected. Infrared (IR) spectra were recorded as thin films or nujol mulls on NaCl plates with a Perkin-Elmer 781 IR spectrophotometer and are expressed in ν (cm -1 ). Nuclear magnetic resonance ( 1 H-NMR and 13 C-NMR) spectra were determined in CDCl 3 , DMSO or CDCl 3 /DMSO (in ratio 1:3) and were recorded on a Varian . Chemical shifts (δ scale) are reported in parts per million (ppm) downfield from tetramethylsilane (TMS) used as an internal standard. Splitting patterns are designated as follows: s, singlet; d, doublet; t, triplet; q, quadruplet; m, multiplet; brs, broad singlet; dd, double doublet. The assignment of changeable protons (OH and NH) was confirmed by the addition of D 2 O. Analytical thin-layer chromatography (TLC) was done on Merck silica gel F-254 plates. For flash chromatography, Merck Silica gel 60 was used with a particle size 0.040-0.063 mm (230-400 mesh ASTM). Elemental analyses were performed on a Perkin-Elmer 2400 spectrometer at Laboratorio di Microanalisi, Dipartimento di Chimica, Università di Sassari (Italy), and were within ±0.4% of the theoretical values. Preparation of azido-acetic acid methyl ester (2). A solution of methyl bromoacetate (84.98 mmol) and sodium azide (9.0 mmol) in DMF (21 mL) was stirred at room temperature for 2.5 h. After the formation of a white solid, an equivalent quantity of water was added and the resulting solution was extracted three times with diethyl ether. The organic layer was washed six times with water and dried with sodium sulphate. The solvent was removed under reduced pressure to obtain a yellow oil. Yield=94%; IR (film) 2120 (N 3 ), 1750 (C=O) cm -1 ; 1 H-NMR (CDCl 3 ) δ 3.90 (s, 3H, OCH 3 ), 3.81 (s, 2H, CH 2 ).
General procedure for the preparation of azidocinnamates 3a and 3b. To a solution of the appropriate aldehyde (1a and 1b) (1 mmol) and 2 (3.4 mmol) in methanol (9 mL) a cold solution of sodium methoxyde (3 mmol) was added. The yellow slurry was stirred at -15°C for 4 h and then ice-cold water (36 mL) was added. The resulting precipitate was filtered off and washed with water.
(E/Z)-2-Azido-3-benzo [1, 3] , 61.27; H, 5.57; N, 5.95. Found: C, 61.34; H, 5.70; N, 6.11 .
General procedures for the preparation of acids 5a and 5b. A suspension of the esters 4a and 4b (2.28 mmol) in 17 mL of 12% KOH solution was heated under reflux for 1 h. The clear solution was poured in ice-cold water and then acidified with HCl 6N. The resulting white precipitate was filtered and washed with water. General procedure for the preparation of the amides 8-16. A suspension of 5a (3.65 mmol) and PCl 5 (5.48 mmol) in anhydrous diethyl ether (25 mL) was stirred at room temperature for 2 h. The solvent was removed under reduced pressure; the residue was washed twice with diethyl ether and then washed three times with chloroform. The acyl chloride obtained was dissolved in anhydrous diethyl ether (25 mL) and a solution of the appropriate amine (5.48 mmol) in 5 mL of dioxane was added dropwise. The mixture was stirred at room temperature for 2 h and the resulting precipitate was filtered and washed with water. , 4.79; N, 9.52. Found: C, 69.16; H, 4.61; N, 3] , 5.40; N, 11.32. Found: C, 63.33; H, 5.21; N, 11.40 . , 4.38; N, 12.17. Found: C, 62.67; H, 4.52; N, 11.91 . General procedure for the preparation of catechols IIIa-IIIh. To a solution of the amides 8-15 (1 mmol) in dichloromethane (70 mL for 8, 100 mL for 9-11, 15 and 200 mL for 12-14) at -40°C and under nitrogen atmosphere, 1M BBr 3 solution in dichloromethane (4 mmol for 8-11 and 8 mmol for 12-15) was added. The mixture was stirred under nitrogen atmosphere at the indicated temperature (-40°C for the amides 8-11 and 0°C for 12-14) for 4 h. The reaction was quenched with methanol, washed three times with methanol and the solvents were removed under reduced pressure. The crude product was purified following method A) or B), depending on the amides. Method A) consisted of silica gel flash column chromatography (eluent petroleum ether-ethyl acetate 4:6 for IIIa and IIIb or ethyl acetate for IIIc and IIId or chloroform-methanol 7:3 for IIIg) and trituration of the solid with diethyl ether-petroleum ether to provide a powder that was filtered off and collected. Method B) consisted of washing with water and trituration of the solid with diethyl ether for IIIe, IIIf and IIIh. , 5.44; N, 9.45. Found: C, 69.05; H, 5.57; N, 9.30 . , 4.49; N, 8.91. Found: C, 61.22; H, 4.44; N, 8.99. 5, droxy-phenyl-ethyl)-amide (IIId). White powder. Yield=47%; mp=221-223°C (dec.); IR (nujol) 3280 (NH), 3320 (OH), 1620 (C=O) cm -1 ; 1 H-NMR (CDCl 3 :DMSO) δ 10.59 (brs, 1H, N), 8.48 (brs, 4H, OH×4), 7.92 (brs, 1H, NH), 6.91-6.62 (m, 5H, Ar-H), 6.50 (d, 1H, Ar-H), 3.60-3.42 (m, 2H, NHCH 2 ), 2.71 (t, 2H, CH 2 ). Anal. Calcd for C 17 H 16 N 2 O 5 : C, 62.19; H, 4.91; N, 8.53. Found: C, 61.97; H, 5.04; N, 8.66. 5, , 4.79; N, 13.12. Found: C, 59.26; H, 4.87; N, 13.11. 5, , 60.27; H, 5.06; N, 12.78. Found: C, 60.38; H, 4.89; N, 12.82. 5, , 5.68; N, 11.87. Found: C, 61.28; H, 5.88; N, , 4.62; N, 12.84. Found: C, 65.71; H, 4.45; N, 12.95. Preparation of 5, . A solution of the acid 5b (9.94 mmol), pentafluorophenol (10.93 mmol) and dicycloexylcarbodiimide (9.94 mmol) in 80 mL of dioxane was stirred at room temperature for 4 h. After the suspen-sion of dicycloexylurea was filtered off, the filtrate was evaporated under reduced pressure. The yellow residue obtained was purified by silica gel flash column chromatography (eluent, petroleum ether-ethyl acetate 8:2). Yield=88%; mp=207-209°C; IR (nujol) 3340 (NH), 1700 (C=O) cm -1 ; 1 H-NMR (CDCL 3 ) δ9.22 (brs, 1H, NH), 7.43 (s, 1H, Ar-H), 7.07 (s, 1H, Ar-H), 6.85 (s, 1H, Ar-H), 3.94 (s, 6H, OCH 3 ×2). Anal. Calcd for C 17 H 10 F 5 NO 4 : C, 52.73; H, 2.60; N, 3.62. Found: C, 52.81; H, 2.75; N, 3.68 .
Preparation of 5,6-dihydroxy-1H-indole-2-carboxylic
acid-pentafluorophenyl ester (7). 1M BBr 3 solution in dichloromethane (3.7 mmol was added to a solution of 6 (1.23 mmol) in 20 mL dichloromethane at -40°C under nitrogen atmosphere. The solution was stirred at the same temperature for 4 h. After addition of water the resulting precipitate was filtered and thoroughly washed with water. Yield=32%; mp=220-221°C (dec.); IR (nujol) 3420 (OH), 3340 (NH), 1700 (C=O) cm -1 ; 1 H-NMR ( Preparation of 5,6-Dihydroxy-1H-indole-2-carboxylic acid- [3-(4-{2-[(5,6- 
A solution of 7 (0.83 mmol) and 1,4-bis-(3-aminopropyl)piperazine (0.27 mmol) in 5 mL of anhydrous DMF was stirred, at 65°C under nitrogen atmosphere, for 16 h. After addition of water the resulting precipitate was filtered, washed with petroleum ether and triturated with diethyl ether to obtain a grey powder. Yield=21%; mp=278-281°C (dec.); IR (nujol) 3300 (OH), 1620 (C=O) cm -1 ; 1 H-NMR (CDCl 3 :DMSO) δ 11.02 (brs, 2H, NH), 6.92-6.81 (s, 4H, Ar-H), 6.60 (s, 2H, Ar-H), 4.10-3.32 (m, 12H, CH 2 ×6), 2.72-2.34 (m, 4H, NHCH 2 ×2), 1.62-1.88 (m, 4H, CH 2 ×2). Anal. Calcd for C 28 H 34 N 6 O 6 : C, 61.08; H, 6.22; N, 15.26. Found: C, 61.27; H, 6.26; N, 15.03.
Biology
Materials, chemicals and enzymes. All compounds were dissolved in DMSO and the stock solutions were stored at -20°C. The γ [ 32 P]-ATP was purchased from either Amersham Biosciences or ICN. The expression systems for the wild-type IN and soluble mutant IN F185KC280S were generous gifts of Dr Robert Craigie, Laboratory of Molecular Biology, NIDDK, NIH, Bethesda, Md., USA. The expression system for the cysteine mutant enzymes was a generous gift of Dr Anna Marie Skalka, Fox Chase Cancer Center, Philadelphia, Pa., USA and the proteins were prepared as previously described (Yi et al., 1999; Asante-Appiah et al., 1998) .
Preparation of oligonucleotide substrates. The oligonucleotides 21top, 5′-GTGTGGAAAATCTCTAGCAGT-3′ and 21bot, 5′-ACTGCTAGAGATTTTCCACAC-3′ were purchased from Norris Cancer Center Core Facility (University of Southern California) and purified by UV shadowing on polyacrylamide gel. To analyse the extent of 3′-processing and strand transfer using 5′-end labelled substrates, 21top was 5′-end labelled using T4 polynucleotide kinase (Epicentre, Madison, Wis., USA) and γ [ 32 P]-ATP (Amersham Biosciences or ICN). The kinase was heatinactivated and 21bot was added in 1.5-molar excess. The mixture was heated at 95°C, allowed slowly cool to room temperature, and run through a spin 25 mini-column (USA Scientific) to separate annealed double-stranded oligonucleotide from unincorporated material.
Integrase assays. To determine the extent of 3′-processing and strand transfer, wild-type IN was preincubated at a final concentration of 200 nM with the inhibitor in reaction buffer (50 mM NaCl, 1 mM HEPES, pH 7.5, 50 µM EDTA, 50 µM dithiothreitol, 10% glycerol (w/v), 7.5 mM MnCl 2 , 0.1 mg/ml bovine serum albumin, 10 mM 2-mercaptoethanol, 10% dimethyl sulphoxide and 25 mM MOPS, pH 7.2) at 30°C for 30 min. Then, 20 nM of the 5′-end 32 P-labelled linear oligonucleotide substrate was added, and incubation was continued for an additional 1 h. Reactions were quenched by the addition of an equal volume (16 µl) of loading dye (98% deionized formamide, 10 mM EDTA, 0.025% xylene cyanol and 0.025% bromophenol blue). An aliquot (5 µl) was electrophoresed on a denaturing 20% polyacrylamide gel (0.09 M tris-borate pH 8.3, 2 mM EDTA, 20% acrylamide, 8M urea).
Gels were dried, exposed in a PhosphorImager cassette, analysed using a Typhoon 8610 Variable Mode Imager (Amersham Biosciences) and quantitated using ImageQuant 5.2. Percent inhibition (%I) was calculated using the equation % I=100 X [1-D-C)/(N -C)], where C, N and D are the fractions of 21-mer substrate converted to 19-mer (3′-processing product) or strand transfer products for DNA alone, DNA plus IN and IN plus drug, respectively. The IC 50 values were determined by plotting the logarithm of drug concentration versus percent inhibition to obtain concentration that produced 50% inhibition.
Cell culture and drug preparation
Human tumour-derived ovarian (HEY ) cells were cultured in RPMI 1640 media supplemented with 10% fetal bovine serum (FBS) and 2 mM L-glutamine at 37°C in a humidified atmosphere of 5% CO 2 . Drugs were prepared in DMSO at a concentration of 10 mM stock solution and stored at -20°C. Further dilutions were freshly made in PBS. 
ND ND -ND ND ND CC 50 cytotoxic concentration 50%; EC 50 , effective concentration 50%; MTT, cytotoxicity assay using ovarian carcinoma cells; ND, not determined. 
Cell viability assay
The cytotoxicity of all drugs was assessed by MTT assay. Briefly, ovarian cancer cells were seeded at a density of 4000 cells/well in 96-well microtitre plates and allowed to attach. Cells were subsequently treated with a continuous exposure to the drugs for 72 h. An MTT solution (at a final concentration of 0.5 mg/ml) was added to each well and cells were incubated for 4 h at 37°C. After removal of the media, DMSO was added and the absorbance was read at 570 nm.
Anti-HIV assays in cultured cell lines
The anti-HIV drug testing performed at the NCI was based on a protocol described by Weislow et al. (1989) . In brief, all compounds were dissolved in DMSO and diluted in 1:100 in cell culture medium. Exponentially growing T4 lymphocytes (CEM cell line) were added at 5000 cells per well. Frozen virus stock solutions were thawed immediately before use, suspended in complete medium to yield the desired multiplicity of infection (~0.1) and added to the microtitre wells, resulting in a 1:200 final dilution of the compound. Uninfected cells with the compound served as a toxicity control, and infected and uninfected cells without the compound served as basic controls. Cultures were incubated at 37°C in a 5% CO 2 atmosphere for 6 days. The tetrazolium salt, XTT [2,3-bis (2-methoxy-4-nitro-5-sulphenyl)-2H-tetrazolium-5-carboxamide], was added to all wells and cultures were incubated to allow formazan colour development by viable cells. Individual wells were analysed spectrophotometrically to quantitate formazan production, and in addition were viewed microscopically for detection of viable cells and confirmation of protective activity.
Molecular modelling
Title compounds II and IIIa-IIIi were constructed with standard bond lengths and angles from the fragment database with MacroModel 6.0 (1997) using a Silicon Graphics O2 workstation running IRIX 6.3. Sybyl 6.2 (2001) was used as graphics platform. Compounds were modelled in neutral form by standard molecular mechanics procedures, with the single exception of DHICA (II). Because the carboxylic group of compound II has a pKa of ~5 under physiological conditions, we used the deprotonated form for our modelling studies. Docking calculations were performed on HP Exemplar Parallel Server V2200 running HP UX 11.0. The atomic charges were assigned using the Gasteiger-Marsili procedure (Gasteiger et al., 1980) . Minimization of structures was performed with the MacroModel/BachMin 6.0 program using the AMBER force fields. Extensive conformational search was carried out using the Monte Carlo/Energy minimization (Chang et al., 1989) for all the compounds considered in the study (Ei-Emin<5 Kcal/mol, energy difference between the generated conformation and the current minimum).
The subunit A of (PDB 1QS4) of the IN-5CITEP complex was selected for all docking studies. The missing residues at positions 141-144 in this subunit were incorporated from monomer B of the IN structure PDB 1BIS after superimposition of the backbones of residues 135-140 and 145-150, as reported previously . Docking was performed with version 3.05 of the program AutoDock (Morris et al., 1998) , using the new empirical free energy function and the Lamarckian protocol as described (Morris et al., 1996) .
Results

Chemistry
The synthetic approach to compounds 5a and 5b and 8-16 used as starting material for the preparation of II, IIIa-IIId and IIIe-IIIi is depicted in Figure 4 . Starting from the aldehydes 1a and 1b and methyl azidoacetate 2, azidocinnamates 3a and 3b were prepared in high yield according to the Hemetsberger reaction (Hemetsberger et al., 1970; Knittel, 1985; Sechi et al., Design and synthesis of novel indole β-diketo acid derivatives as HIV-1 integrase inhibitors, under review). Intermediates 3a and 3b were converted into the esters 4a and 4b in refluxing xylene from which, on alkaline hydrolysis, the expected acids 5a and 5b were obtained in 98% yields. Deprotection of the catechol moiety with BBr 3 in dichloromethane at -40°C gave the expected DHICA II (Figure 4) .
The intermediate 5a was treated with PCl 5 and the acyl chloride was then coupled with the appropriate amines to give the amides 8-16. Deprotection of the catechol moiety was carried out as described above to obtain the desired compounds IIIa-IIIh. Since compound IIIi could not be obtained by this route, we used the intermediate 5b that was converted into the pentaflurophenyl ester 6. The latter was first deprotected into 7 and then reacted with 1,4-bis(aminopropyl)-piperazine in DMF at 65°C to give IIIi in 21% yield. Table 1 summarizes the in-vitro results of the title compounds II, IIIa-IIIi and intermediates 8-16. Inhibition of IN catalytic activities, 3′-processing and strand transfer reactions were carried out using oligonucleotide-based assays as described . All target compounds (II and IIIa-IIIi) showed anti-IN activity in enzyme assays at low micromolar concentrations. In general, all the tested compounds showed equal potency against both 3′-processing and strand-transfer activities of purified IN. This fact prompted us to postulate that most of these compounds are tightly bound to the pre-assembled IN-DNA complex. 
Inhibition of HIV-1 IN catalytic activities
Discussion
II, IIIb, IIIc, IIIe, IIIf, IIIh and IIIi with IC 50 values ranging from 2-11 µM showed similar potency to that of reference compound I (IC 50 =5 µM) (Zhang et al., 2001) against purified IN.
The monomer II with IC 50 =6.5 ±1 µM and 6 ±1 µM against 3′-processing and strand transfer activities, respectively, proved to be one of the most potent compounds. The high potency of DHICA (II) could be explained by its unique arrangement in the IN active site, as detailed below. The interaction of catechol with K159, as well as D64 with indolic N-H and coordination with a Mg 2+ cation in the IN active site, could be responsible for high inhibitory potency of compounds IIIb and IIIc. Substitution of the carboxyl group of II with amide functionality led to compound IIIa, which was about 5-fold less active. SAR studies suggested that the anti-IN activity of IIIa could be slightly increased, either by substitution of the aromatic hydrogen with a cathecol system (compare IIIa and IIIc), or by elongation of the alkylamide chain by one methylene unit (compare IIIa and IIIb). A decrease in anti-IN potency was observed when a cathecol system was added to IIIb to obtain IIId. With the exception of IIIg, dimerization of II to obtain compounds IIIe-IIIi did not lead to a significant variation in activity. In the case of IIIe-IIIg, a rough correlation between length of linker and activity could be observed. In fact, the best activity was exhibited by compound IIIf with IC 50s =3 ±1 µM and 2.3 ±1.3 µM for 3′processing and strand transfer, respectively). Analogue IIIg was significantly less potent. Also, IIIh and its corresponding flexible analogue IIIi displayed potent inhibitory activities. On the other hand, the protected catechol intermediates 8-16 did not show significant activity at the highest tested concentration (200 µM). This clearly indicates that the free catechol functionality is necessary for a strong interaction with the catalytic residues.
The above compounds potentially chelate divalent metal ions. In addition it has been proposed that compounds, such as mercaptosalicylhydrazides that chelate Mg 2+ ions in the active site of IN, bind to the C65 residue . Therefore we wanted to test the hypothesis M Sechi et al.
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©2004 International Medical Press that C65 binding is important for activity. The top-ranking compounds IIIe, IIIf and IIIh were active against the C65S (Yi et al., 1999) mutant, which implies that this residue does not bind to these compounds. Interestingly, while I was half as active against the C65S mutant as the wild type IN (Zhang et al., 2001) , IIIh showed 10 times greater potency against the C65S mutant than the wild type IN. In this case, the mutation of Cys to Ser could be favourable for the inhibitory activity of IIIh. IIIe and IIIf inhibited both enzymes with similar potency. It is also noteworthy that IIIe, IIIf and IIIh were 1.6-, 2.5-and 25fold more active than I against C65S, respectively.
Molecular modelling
Previously, several computational docking studies using the IN-5CITEP co-crystal structure (Goldgur et al., 1999) were reported Polanski et al., 2002; Ouali et al., 2000) . We applied similar docking procedure to investigate the interactions of II and IIIa-IIIi, with the amino acid residues of the IN catalytic site. The results of clusterized docking runs with the most favourable free binding energy for each compound are given in Table 2 . Graphical representations of top-ranking binding modes obtained for II, IIIb, IIIc, IIIf and IIIi showing the important residues involved in binding are depicted in Figure 5 and Table 3 . According to docking results, the amino acid residues involved in the binding of title compounds located near the catalytic site were as follows: D64, C65, T66, H67, T115, F139, P142, N144, Q146, S147, Q148, N155, K156 and K159. Several of these were considered to be very important for the activity of IN and to some have been previously shown to play a role in substrate binding . In general, different ligands showed different binding modes with some overlapping features, which were predicted as potential H-bonds and van der Waals interactions. In order to better analyse the docking results, the structures of title compounds were divided into two main groups constituted by monomers II, IIIa-IIId and dimers IIIe-IIIi. Compound II was found to bind to both K156 and K159, two sites important for DNA and mononucleotide binding ( Jenkins et al., 1997; Esposito et al., 1998; Drake et al., 1998) . In addition, II also interacts with T66 (through the indole NH), D64 and C65, both residues located near the Mg 2+ (through the indole catechol group). On the other hand, the active monomeric derivatives (IIIa-IIId) showed different orientation patterns and binding modes within the IN active site. In fact, they form H-bonds with either K156 or K159 through the indole catechol (IIIa, IIIb and IIId) or the phenyl (IIIc) moieties. Moreover, they were found to share similar binding with D64 through their indole NH (IIIb-IIId) or carboxamide group (IIIa), and with either C65 (IIIb) or T66 (IIIc and IIId) through the catechol groups of the indole (IIIb and IIId) or phenyl (IIIc) moieties.
The plane of the indole of IIIa is rotated by approximately 180°with respect to that of IIIb and IIId, and D64 interacts with the NH of the amide function rather than with the indolic NH. This could be the reason for the significantly lower anti-IN activity of IIIa with respect to IIIb and IIId. However, the opposite disposition in the IIIc site did not influence the activity. This observation can be consistent with the additional interaction by the indolic catechol with Q148. This confirms that the HIV-1 IN active site is quite large and relatively shallow and therefore able to accommodate large variations in ligand size and shape with different binding modes. The lower activity of the dimer IIIg may be explained considering that this compound does not interact with K156, K159 and D64, a recurrent motif important for activity.
Dimeric compounds IIIe-IIIi interact with additional binding regions and significantly differ on their positions on the IN active site. While half of the molecule occupies the same space as monomers (the west binding region, as discussed by Buolamwini et al., 2002) , the other half uses the area in front of the two catalytic aspartates but without contacting them (east binding region). With the exception of IIIh, all dimers establish H-bonds with T66 through one of the cathecol oxygens (interaction on the west region) while the other oxygen interacts with either C65 (IIIe) or K159 (IIIf and IIIi). The indole catechol of IIIh instead H-bonds with both K156 and K159. Moreover, indolic NH displayed H-bonding with either N155 (IIIe and IIIh) or D64 (IIIi) while the carboxamide group interacts with Q148 (IIIe) or D64 (IIIi). On the east binding region the other indole catechol portion establishes H-bonds with both P142 and N144 (IIIe and IIIf) and with either N144 (IIIg) or Q146 (IIIi). Our docking results indicated that the estimated free binding energy values and corresponding inhibition constant (Ki) values were, in general, higher than the IC 50 values obtained experimentally.
Cytotoxicity and antiviral activity
Previously, it was shown that hydroxylated aromatics show significant cytotoxicity and some can cross-link proteins (Stanwell et al., 1996) . It was recently shown that catecholcontaining compounds are potent inhibitors of lipoxygenase and inhibit cell growth in low micromolar concentration (Simpson et al., 2003) . In our cancer screen, none of the target compounds showed significant activity against ovarian carcinoma cells. Interestingly, some of the protected compounds (13, 14 and 15) showed significant cytotoxicity. Surprisingly 14 displayed high cytotoxicity against HEY cells (CC 50 =0.1 ±0.01 µM) and studies are underway to determine its mechanism of cytotoxicity.
When we expanded our study to include cytoprotection activity of the title compounds II and IIIa-i as well as 8-16 against HIV-1-infected CEM cells we observed that the target compounds II and IIIa-IIIi were toxic and did not yield therapeutic efficacy. These observations are consistent with previous studies (Burke et al., 1995; Neamati, 2002) . We also observed that none of the protected compounds 8-16 showed antiviral activity at the highest tested concentration (200 µM).
